Synopsis: Shares fell over 5 percent on Thursday amid multiple concerns, including US tariff fears, high exposure to branded pharmaceuticals, product-specific pressures, and geopolitical uncertainties in the Middle East.
The share of this company, which offers a wide range of affordable, high-quality medicines, including specialty products, generics, and APIs across 100+ countries, with a strong presence in chronic and complex therapies.
With the market capitalization of Rs 4,05,118 crore, Sun Pharmaceutical Industries Ltd’s shares on Thursday made a day low of Rs 1635.05 per share, down by 5.4 percent from its previous day’s close price of Rs 1728.45 per share. The shares of the company have given a return of 176 percent over the last five years.
Key Reasons Behind the Decline
- Tariff Concerns Hit Shares: Sun Pharma shares fell as much as 6 percent on Thursday, April 2, after reports suggested the Trump administration may impose tariffs on drugmakers without agreements to lower US prices. Potential 100 percent tariffs on imported branded medicines triggered investor caution.
- High US Exposure Amplifies Risk: The company’s significant reliance on US-branded pharmaceuticals has fueled worries. US sales accounted for 31 percent of overall revenue in FY25, led by specialty and innovative medicine portfolios, making Sun Pharma particularly sensitive to policy changes and tariff risks.
- Product-Specific and Market Pressures: Broader market actions, including global drugmakers increasing US production and inventory, added to the pressure. Key products such as Illumya, Winlevi, and Cequa could face pricing and regulatory challenges, contributing to heightened uncertainty and selling pressure on the stock.
- Middle East Uncertainties Impact Sentiment: Ongoing geopolitical tensions in the Middle East have added to investor caution for Sun Pharma. Concerns over supply chain disruptions, potential regulatory challenges, and regional instability have heightened market uncertainty, further weighing on the stock alongside tariff and US market exposure risks.
About the Company
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company and its subsidiaries have various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to the global market.
Financial Highlights: The revenue from operations grew by 13.4 percent to Rs 15,521 crore in Q3 FY26, corresponding to the same quarter in the last financial year, and the operating margin grew from 29 percent to 32 percent YoY. Accompanied by a net profit growth of 16 percent to Rs 3,381 crore in Q3 FY26 from Rs 2,913 crore in Q3 FY25, resulting in EPS growth of 16 percent YoY to Rs 14.04 per share in Q3 FY26.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Why Did Sun Pharma Shares Fall 5% in Today’s Trading Session? Check the Reasons appeared first on Trade Brains.